Fidelity Disruptive Technology ETF Is Down 12% in 2026 and This Catalyst Could Decide What Comes Next

Fidelity Disruptive Technology ETF (FDTX) has 0% healthcare sector exposure, so it is not a biotech or health-sciences ETF. Investors who landed on FDTX expecting biotech allocation should reassess holdings or seek a different fund if they need explicit healthcare/biotech exposure.

Analysis

Fidelity Disruptive Technology ETF (FDTX) has 0% healthcare sector exposure, so it is not a biotech or health-sciences ETF. Investors who landed on FDTX expecting biotech allocation should reassess holdings or seek a different fund if they need explicit healthcare/biotech exposure.